Nyxoah S.A. is a medical technology company focused on developing and commercializing innovative therapeutic solutions for the treatment of obstructive sleep apnea (OSA). Their primary product features a novel implantable neurostimulator designed to improve airway muscle function during sleep, thereby reducing the frequency of breathing disruptions caused by OSA. Nyxoah's approach offers a minimally invasive alternative to traditional continuous positive airway pressure (CPAP) therapy, aimed at enhancing patient comfort and compliance. The company is dedicated to advancing the understanding and treatment of sleep disorders, striving to improve the quality of life for patients worldwide. Read More
Nyxoah (NASDAQ:NYXH) used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability.
Chief Executive Officer Olivier Taelman said there is “a lot of excitement in
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.
Chief Executive Officer Olivier Taelman said
